izpis_h1_title_alt

NDMA formation due to active ingredient degradation and nitrite traces in drug product
ID Golob, Nejc (Avtor), ID Peterlin, Simona (Avtor), ID Grahek, Rok (Avtor), ID Roškar, Robert (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (1,30 MB)
MD5: D268C6B83026B705F8EA90E0DE7E161E
URLURL - Izvorni URL, za dostop obiščite https://www.sciencedirect.com/science/article/pii/S0022354923001077 Povezava se odpre v novem oknu

Izvleček
N-nitrosamines are genotoxic compounds which can be found as impurities in drug substances and drug products used in the pharmaceutical industry. To date, several possible nitrosamine sources in drug products have been reported and this study aims to illuminate another one. A case of afatinib drug product was investigated, in which up to 50 ppb N-nitrosodimethylamine (NDMA) traces were detected. Afatinib was found to degrade to the secondary amine dimethylamine (DMA), forming NDMA with traces of nitrite in crospovidone. Two series of film-coated tablets were prepared with crospovidone from two different manufacturers, containing different levels of nitrites. Tablets were subjected to an accelerated stability study (40 °C/75% relative humidity) or stored at room temperature and levels of NDMA, DMA and nitrite in tablets were monitored. NDMA and nitrite were found on ppb levels, whereas DMA was detected on ppm levels. NDMA formation in the drug product was found to be time, temperature and nitrite dependent and it was emphasized that DMA and nitrite should be reduced. The accelerated stability study proved to be a useful tool for predicting nitrosamine formation in the drug product.

Jezik:Angleški jezik
Ključne besede:N-nitrosodimethylamine, NDMA, afatinib drug product, drug substance degradation, dimethylamine, DMA, nitrite, excipient, crospovidone, stability study
Vrsta gradiva:Članek v reviji
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:FFA - Fakulteta za farmacijo
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2023
Št. strani:Str. 1277-1286
Številčenje:Vol. 112, iss. 5
PID:20.500.12556/RUL-148688 Povezava se odpre v novem oknu
UDK:661.12
ISSN pri članku:0022-3549
DOI:10.1016/j.xphs.2023.03.007 Povezava se odpre v novem oknu
COBISS.SI-ID:146220547 Povezava se odpre v novem oknu
Datum objave v RUL:29.08.2023
Število ogledov:506
Število prenosov:188
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Journal of pharmaceutical sciences
Skrajšan naslov:J. pharm. sci.
Založnik:Elsevier, American Pharmacists Association
ISSN:0022-3549
COBISS.SI-ID:25777152 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:N-nitrozodimetilamin, NDMA, zdravilo afatinib, razgradnja zdravilne učinkovine, dimetilamin, DMA, nitriti, pomožne snovi, krospovidon, stabilnostne študije, farmacevtska industrija

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj